GlassScriptPhysician profile
Justin Harrell
NPI 1346744323
$1,600.76
in general payments reported to CMS, 2019-2025
21 companies · $61.02 in 2025
The $61.02 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $35.92 · 2022: $270 · 2023: $628 · 2024: $605 · 2025: $61.02.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,294.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,294.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $317.85 | 2022-2024 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $187.86 | 2021-2023 | Camzyos |
| Biosense Webster, INC. | $160.39 | 2023-2025 | Carto 3, Soundstar |
| Atricure, INC. | $148.50 | 2024 | |
| Boston Scientific Corporation | $108.78 | 2023-2024 | Watchman Flx |
| Amgen INC. | $79.06 | 2022-2024 | Repatha |
| United Therapeutics Corporation | $74.00 | 2023-2024 | Tyvaso |
| Kiniksa Pharmaceuticals International, Plc | $70.84 | 2024 | Arcalyst |
| Janssen Pharmaceuticals, INC | $67.13 | 2023-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $57.58 | 2022-2024 | Wainua, Farxiga |
| Medtronic, INC. | $57.24 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $47.27 | 2023-2024 | Uptravi, Opsumit |
| Teleflex LLC | $42.29 | 2022-2024 | Vascband |
| Sanofi-Aventis U.S. LLC | $37.17 | 2024 | |
| Novartis Pharmaceuticals Corporation | $29.77 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, LTD. | $26.23 | 2023 | Arcalyst |
| Daiichi Sankyo INC. | $24.98 | 2023 | Injectafer |
| Merck Sharp & Dohme LLC | $18.12 | 2023 | Verquvo |
| Inogen, INC. | $17.37 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.78 | 2023 | |
| Pfizer INC. | $13.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Harrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.